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Stromal cells are essential components of the bone marrow (BM) microenvironment that regulate and support the survival
of different tumors, including chronic lymphocytic leukemia (CLL). In this study, we investigated the role of Notch signaling
in the promotion of survival and chemoresistance of human CLL cells in coculture with human BM-mesenchymal stromal
cells (hBM-MSCs) of both autologous and allogeneic origin. The presence of BM-MSCs rescued CLL cells from apoptosis both
spontaneously and following induction with various drugs, including Fludarabine, Cyclophosphamide, Bendamustine, Prednisone
and Hydrocortisone. The treatment with a combination of anti-Notch-1, Notch-2 and Notch-4 antibodies or g-secretase inhibitor XII
(GSI XII) reverted this protective effect by day 3, even in presence of the above-mentioned drugs. Overall, our ﬁndings show that
stromal cell-mediated Notch-1, Notch-2 and Notch-4 signaling has a role in CLL survival and resistance to chemotherapy. Therefore,
its blocking could be an additional tool to overcome drug resistance and improve the therapeutic strategies for CLL.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common lympho-
proliferative disorder characterized by a variable clinical course
according to well-deﬁned prognostic factors, such as mutation
status of V genes, CD38 and ZAP-70 expression and speciﬁc
gene proﬁles. CLL is characterized by the clonal expansion of
mature, antigen-stimulated CD5
þ/CD23
þ cells in blood, second-
ary lymphoid tissues and bone marrow (BM), in close contact with
stromal microenvironment.
1,2 The complex interactions among
growth factors, extracellular matrix components and stromal cells
provide extrinsic signals that regulate growth, differentiation and
survival of normal B-cell precursors and neoplastic B cells, such as
CLL cells and B lymphoblasts.
1–5 Stromal cell integrins are involved
in regulating leukemia cell survival through the interaction with
the extracellular matrix;
6 when CLL cells are removed from the
in vivo stromal microenvironment and placed in culture without
supportive stroma, they undergo spontaneous apoptosis.
7 CLL cell
coculture with different adherent cell types, collectively referred to
as stromal cells, leads to leukemia cell survival, migration and
resistance to drugs such as Fludarabine,
4,5,8,9–14 thus highlighting
the importance of external signals by accessory cells. Supportive
microenvironmental cells include BM-mesenchymal stromal
cells (BM-MSCs),
8,10 CD68
þ nurse-like cells derived from
monocytes,
10–13 and follicular dendritic cells.
14,15 BM-MSCs are
multilineage non-hematopoietic progenitor cells that have a
key role in supporting lympho-hematopoiesis, and give rise
to different stromal cell lineages, including BM ﬁbroblasts,
adipocytes, osteocytes and chondrocytes, as shown in vitro and
partially in vivo.
16,17 Stromal cell cocultures are used to mimic the
in vivo microenvironment and to develop strategies to overcome
stroma-derived drug resistance.
18 Previous studies reported that
the adhesion to stroma of hematopoietic malignant cell lines,
including myeloma, acute and chronic myeloid leukemia and
CLL, confers resistance to a variety of cytotoxic drugs, as well as
Fas-mediated cell death.
8,19,20
Notch signaling is an evolutionarily conserved molecular
pathway that has a pivotal role in cell fate and differentiation in
many tissues during both embryonic and postnatal develop-
ment.
21,22 Four mammalian Notch receptors have been identiﬁed
and designated as Notch1–4.
21,22 The interactions of Notch
receptors with membrane-bound ligands of Delta and Jagged
families, that is, delta-like ligand (DLL)-1/-3/-4, Jagged-1 and -2,
are critical for Notch signaling.
21,22 Ligand binding induces
g-secretase-mediated cleavage and translocation of Notch
intracellular domain into the nucleus, where it interacts with
the DNA-binding protein RBP-J to induce the expression of
numerous downstream target genes, such as Hes-1 and Deltex-1.
22
Jagged-1/-2 and DLL-1, commonly named as Delta/Serrate/LAG-2
(DSL) proteins, are ligands for Notch 1–4;
22,23 Delta-4 can bind
and activate Notch-1 and -4 receptors,
22–24 whereas Delta-3 can
bind and activate Notch-1 or similar Notch receptors.
22,25
Human BM-MSCs (hBM-MSCs) express a number of Notch
ligands
26,27 that are still present in MSC progeny; in addition,
MSC-derived osteoblasts regulate hematopoietic stem cell niche
through Jagged-1/Notch-1 signaling.
27 Notch system is crucial
during hematopoiesis and embryonic development
27,28 and its
dysregulation is associated with several human disorders,
including cancer.
28–30 A pivotal role for Notch signaling has
been clearly shown in promoting survival and apoptosis resistance
in T/B-cell acute lymphoblastic leukemia and CLL.
3,31–33 However,
a few data are available on both the expression of different Notch
molecules by CLL cells
33 and the link between Notch signaling
and the stromal cell-mediated molecular mechanisms involved in
this phenomenon. Therefore, we evaluated the contribution of
1Department of Medicine, Section of Hematology, Stem Cell Research Laboratory, University of Verona, Verona, Italy and
2Department of Pathology, Section of Pathological
Anatomy, University of Verona, Verona, Italy. Correspondence: Dr M Krampera, Department of Medicine, Section of Hematology, Stem Cell Research Laboratory, University of
Verona, Policlinico GB Rossi, P.le L. Scuro, 10, 37134 Verona, Italy. E-mail: mauro.krampera@univr.it or www.stemcellsreslab-verona.it
Received 1 February 2012; revised 27 March 2012; accepted 3 April 2012
Citation: Blood Cancer Journal (2012) 2, e73; doi:10.1038/bcj.2012.17
& 2012 Macmillan Publishers Limited All rights reserved 2044-5385/12
www.nature.com/bcjdifferent Notch molecules to survival and chemoresistance of
human primary CLL cells in coculture with autologous and
allogeneic BM-MSCs.
MATERIALS AND METHODS
Cell collection
CLL cells were obtained after informed consent from peripheral blood
samples of 12 patients with newly diagnosed CLL, according to the
Institutional guidelines. Cells were isolated by Ficoll–Hypaque centrifuga-
tion (Pharmacia, Uppsala, Sweden) and characterized by immunopheno-
typing. Most cells were CD19
þ/CD5
þ/CD23
þ CLL cells, as assessed by
ﬂow cytometry (median: 97.0%; range: 95.9–99.0). Human CD73
þ/CD45
 
BM-MSCs were obtained after informed consent from BM samples
collected from both ﬁve healthy donors and ﬁve CLL patients (hBM-
MSCs*) to carry out both allogenic and autologous coculture experiments.
CLL patients characteristics are described in Supplementary Table 1. As
deletions in p53 gene have been reported to increase signiﬁcantly CLL cell
survival as compared with CLL with intact p53 signaling, we selected all
cases with wild-type p53 (including the CLL7 case, displaying del17
aberration) to avoid any additional factor that could inﬂuence the role of
Notch signaling in the experiments with MSCs.
Expansion and immunophenotype characterization of MSCs
Both hBM-MSCs and hBM-MSCs* were seeded at a density of 3.1 10
4
cells/cm
2 and cultured in Dulbecco’s modiﬁed Eagle medium with 20%
fetal bovine serum, 1% L-glutamine, and penicillin–streptomycin (Gibco,
Milan, Italy), at 371Ci n5 %C O 2 and humidiﬁed atmosphere, as previously
described.
21,29 hBM-MSCs and hBM-MSCs* at passage 2 or 3 displayed
homogeneous mesenchymal immunophenotype (including CD105, CD44,
CD73, CD146 marker expression) and multipotent differentiation potential
(into osteoblastic, adipocytic and chondrocytic lineages), and were used
for the coculture experiments.
26,31,34
Coculture of CLL cells with MSCs
CLL cells were cultured alone or cocultured with either hBM-MSCs or hBM-
MSCs* at 10/1 ratio for 3, 7 and 28 days to study the capability of MSCs of
supporting CLL cell survival. The expression of Notch molecules on both
cell types was evaluated at days 3 and 7; most of the other experiments
were performed after 3 days of culture.
Experiments with or without inhibitors or blocking antibodies against
Notch molecules were carried out in 96-well plates with a conﬂuent
monolayer of MSCs: 10
5 CLL cells were cultured in 200ml RPMI 1640
medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and
1% penicillin–streptomycine, with or without 10
4 adherent hBM-MSCs or
hBM-MSCs*. Media collected from the 1-day MSC culture was added to CLL
cell culture to study the effects of the soluble factors produced by MSCs. To
address whether these soluble factors are Notch-related, CLL cells were
cocultured either with hBM-MSCs or hBM-MSCs* at 10/1 ratio in Transwell
conditions for 3 days with or without either g-secretase inhibitor GSI-XII
(X-IL-CHO) or blocking antibodies against Notch molecules. Other inhibitors,
such as GSI-I (Z-LLNle-CHO) and GSI-IX (DAPT) did not lead to the complete
block of Notch signaling pathway and therefore were not employed (data
not shown). Cocultured CLL cells were separated from hBM-MSCs or hBM-
MSCs* monolayer by careful pipetting with ice-cold phosphate-buffered
saline. Viable cells were identiﬁed by using the Trypan blue dye exclusion
method and counted in a hemocytometer.
Coculture of CLL cells with MSCs in presence of GSI XII and
chemotherapeutic agents
Stock solutions of GSI XII, Fludarabine and Cyclophosphamide were
purchased from Calbiochem (La Jolla, CA, USA), and Bendamustine,
Prednisone and Hydrocortisone from Sigma-Aldrich (Saint Louis, MO, USA).
GSI XII and Fludarabine were resuspended in dimethyl sulfoxide as a
vehicle. Cyclophosphamide, Bendamustine, prednisone and hydrocorti-
sone were diluted in 0.9% Sodium Chloride (NaCl); all reagents were
diluted to appropriate concentrations with culture medium.
GSI XII, Notch-speciﬁc neutralizing antibodies and chemotherapeutic
agents were titrated in subsequent experiments to determine the
lowest efﬁcient dose leading to speciﬁc Notch inhibition and induction
of apoptosis. The effective concentration killing 50% of CLL cells
(EC50) derived from the equations that best ﬁt the linear range of the
dose-response curve. The speciﬁc relative sensitivity of CLL cells to GSI XII
was performed by culturing alone or coculturing CLL cells with hBM-MSCs
for 3 days in presence of increasing concentrations of GSI XII. The effects of
increasing concentrations of GSI XII on hBM-MSCs-induced survival of CLL
cells were evaluated after 3 days of co-culture at 10/1 and 1/1 ratios. CLL
cells were then cultured without or with hBM-MSCs at 10/1 ratio in
absence or presence of chemotherapeutic agents, and without or with
blockade of Notch pathway for 3 days. Percentage of speciﬁc apoptosis
was calculated according to the following formula: (test (inhibitor-induced
apoptosis)–control (spontaneous apoptosis)) 100/(100–control).
35
Flow cytometric analysis of Notch molecules expression, treatment
procedure with inhibitors and neutralizing anti-Notch molecule antibodies,
assays with recombinant Notch ligands and interleukin (IL)-6/-7, as well as
annexinV/7AAD apoptosis assay, cell cycle analysis, measurement of
caspase activity, immunoﬂuorescence staining, and western blot analysis
were performed as previously described.
27 Monoclonal antibodies were
used to detect Jagged-2 (R&D Systems, Minneapolis, MN, USA), DLL-1 (R&D
Systems), Notch-1 (BD Biosciences, San Jose, CA, USA), Bcl-2 (clone 124–
Dakocytomation, Carpinteria, CA, USA), p53 (BD Biosciences), VEGFR2 (KDR)
(R&D Systems), caspase-3 Cell Signaling Technology, Danvers, MA, USA,
poly(ADP-ribose) polymerase (PARP) (Cell Signaling Technology), CD127
(IL-7R, Immunotech, Marseille, France), NF-kB (Cell Signaling Technology),
protein 2 (c-IAP2) (R&D Systems), Jagged-1 (Cell Signaling Technology),
Notch-2 (LifeSpan Biosciences, Seattle, WA, USA), Notch-3 (Abcam plc,
Cambridge, MA, USA), Notch-4/DLL-3 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), DLL-4 (Abcam plc), all with IgG isotype controls. Directly
conjugated monoclonal antibodies anti-CD19, CD23 and CD5 were from
Becton Dickinson (San Jose, CA, USA). Cells displaying Notch molecules
were expressed as either percentage of positive cells, in case of bi-modal
ﬂuorescence distribution, or mean ﬂuorescence intensity (MFI), after
electronic gating of CLL cells, hBM-MSCs or hBM-MSCs*. In case of uni-
modal ﬂuorescence distribution, MFI was calculated as the geometric
mean of ﬂuorescent intensity of hBM-MSCs, hBM-MSCs* or CLL cells
expressing Notch molecules.
Neutralizing antibodies were used at the following concentrations: anti-
human Notch-1 (Genetex, Irvine, CA, USA), -2 and -3 (R&D Systems) 10mg/
ml; goat anti-human Notch-4 (Santa Cruz Biotechnology) 5mg/ml; goat
anti-human Jagged-1/-2, DLL-1/-3 and -4 (R&D Systems) 10mg/ml. Blocking
antibodies against Notch molecules and appropriate isotype controls were
added to CLL cells or MSCs before their mixing in coculture.
Statistical analysis
Statistical analysis was performed by using one-way analysis of variance
test to compare multiple groups with Holm–Sidak test used for internal
comparison between multiple groups. P value p0.05 was considered
statistically signiﬁcant. Results were expressed as the mean±SD of 12
independent experiments from different human CLL donors. All statistical
calculations were performed using STATA, Version 10.0 (StataCorp, College
Station, TX, USA).
RESULTS
Expression of Notch receptors and ligands by CLL cells and MSCs
in culture and coculture conditions
Flow cytometry analysis of the expression of Notch molecules by
CLL cells and hBM-MSCs in culture and coculture at day 3 and 7 is
shown in Table 1. Freshly isolated CLL cells expressed high levels
of all Notch receptors and ligands except DLL-1, which was
detected only at low levels. No signiﬁcant differences in the
expression of Notch receptors and ligands by CLL cells were
observed according to Zap-70 expression or mutational status of
V genes (data not shown). hBM-MSCs* showed the same pattern
of expression as hBM-MSCs, except Notch-1 that was expressed
3.4-fold higher than hBM-MSCs at basal levels. Following CLL cell
and hBM-MSC coculture (3 or 7 days), upregulation of Notch-1
and -4 by CLL cells was observed. Similarly, Notch-2 expression
was induced in hBM-MSCs at day 7. By contrast, Notch-3 was
signiﬁcantly downregulated at day 3. Furthermore, Notch3
expression was signiﬁcantly reduced in CLL cells cultured with
BM-MSCs* at both timepoints examined and with hBM-MSCs for
7 days. Notch-1 expression by hBM-MSCs cultured alone was
similar to that observed during the coculture, whereas Notch-4
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lated by CLL cells but not by hBM-MSCs, whereas DLL-4 was
signiﬁcantly downregulated following coculture for 3 days. In
addition, DLL-1 expression by hBM-MSCs was not observed during
coculture, and the expression of Jagged-1 and -2 did not
signiﬁcantly change in hBM-MSCs after 3-day coculture, as well
as the expression of DLL-3 after 7-day coculture. The expression of
the different Notch molecules by CLL cells in coculture with hBM-
MSCs or hBM-MSCs* is shown in Table 1.
Effects of Notch pathway inhibition and drugs on CLL cell survival
and MSC functions
Dose-response curve showing the effects of increasing concentra-
tions of GSI XII and drugs on CLL cells cultured alone for 1 day is
shown in Figure 1. Treatment with increasing concentrations
of Fludarabine, Cyclophosphamide, Bendamustine, Prednisone
and Hydrocortisone resulted in a dose-dependent decrease in
CLL cell viability, with EC50 47.5, 4100.0, 4200.0, 4100.0
and 4100.0mM, respectively. GSI XII did not kill CLL cells at
concentrations below 2.5mM; however, higher concentrations
promoted speciﬁc apoptosis of CLL cells, with EC50 410.0mM.
On the other hand, apoptosis or morphological changes of hBM-
MSCs in culture for 3 days in presence of GSI XII, Fludarabine,
Cyclophosphamide, Bendamustine, Prednisone and Hydrocorti-
sone were observed up to 15.0, 40.0, 358.3, 500.0, 279.0 and
200.0mM concentrations, respectively. Apoptosis signs or clear
morphological changes were observed in hBM-MSCs treated with
GSI XII and Hydrocortisone at concentrations of 40 and 10000mM,
respectively (data not shown). Active caspase-3 expression was
not induced in hBM-MSCs cultured alone for 3 days in presence of
GSI XII, Fludarabine, Cyclophosphamide, Bendamustine, Predni-
sone and Hydrocortisone at concentrations up to 15.0, 40.0, 358.3,
500.0, 279.0 and 200.0mM, respectively (Figure 2). As activation of
caspase-3 is a hallmark of death receptor-mediated apoptosis,
these results demonstrate that inhibition of signaling pathways
with small-molecule inhibitors may promote death receptor-
mediated apoptosis, as shown by heat-shock proteins inhibition.
36
In addition, GSI XII and drugs did not signiﬁcantly affect
mesenchymal marker expression (data not shown).
Effects of GSI XII on MSC-mediated survival of CLL cells
Coculture of CLL cells with hBM-MSCs signiﬁcantly increased the
number of surviving CLL cells, as compared with what obtained
by culturing CLL cells alone in similar conditions
7–9 (Figure 3a). At
low concentrations, GSI XII had no detectable speciﬁc cytotoxic
effects on CLL cells either cultured alone or cocultured for 3 days
with hBM-MSCs at 10/1 and 1/1 ratios (Figures 3b and c). GSI XII
was capable of signiﬁcantly inhibiting speciﬁc apoptosis of CLL
cells cultured alone and cocultured with hBM-MSCs (1/1 ratio) at
Table 1. Notch receptor and ligand expression by CLL cells and MSCs
Notch-1 Notch-2 Notch-3 Notch-4
Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7
Expression by CLL cells
a. Alone 2.6±0.8 1.6±0.5 17.6±4.3 40.4±8.3 23.1±4.6 28.3±5.6 11.1±2.3 6.3±1.8
b.þhBM-MSCs 3.8±1.3 3.7±0.9 21.7±5.6 44.1±7.1 18.3±5.4 23.1±5.2 21.5±4.4 14.8±3.3
c.þhBM-MSCs* 3.2±0.9 2.8±1.1 16.6±4.5 41.4±9.1 12.2±2.6 16.8±4.8 12.2±3.2 14.1±2.5
a. versus b. NS Po0.05 NS NS NS NS Po0.05 Po0.05
b. versus c. NS NS NS NS NS NS Po0.05 NS
a. versus c. NS NS NS NS Po0.05 Po0.05 NS Po0.05
Expression by MSCs
a. Alone 4.0±1.5 3.7±1.1 7.1±1.8 7.8±1.6 13.1±3.1 8.7±2.7 9.9±2.1 9.7±2.8
b.þhBM-MSCs 3.9±1.4 2.6±1.3 5.6±1.6 14.5±4.3 5.3±2.4 9.9±3.9 5.3±1.6 5.5±1.2
c.þhBM-MSCs* 4.6±1.7 3.3±1.4 6.8±1.9 11.6±3.2 8.8±3.1 10.5±3.3 7.0±2.3 6.2±2.1
a. versus b. NS NS NS Po0.05 Po0.05 NS Po0.05 Po0.05
b. versus c. NS NS NS NS NS NS NS NS
Jagged-1 Jagged-2 DLL-1 DLL-3 DLL-4
Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7
Expression by CLL cells
a. Alone 10.0±2.5 6.8±2.8 10.4±2.5 12.1±3.0 9.2±3.5 3.2±1.5 11.0±3.2 15.2±4.0 13.9±4.8 13.2±3.7
b.þhBM-MSCs 18.4±3.1 1.5±0.3 13.1±4.5 16.6±4.6 1.0±0.5 2.4±0.7 19.7±4.1 20.0±5.2 20.3±6.4 22.0 ±7.5
c.þhBM-MSCs* 7.5±2.8 1.3±0.1 6.1±2.1 12.7±5.7 3.0±0.7 2.6±0.9 20.6±4.7 21.0±6.8 20.6±5.7 23.0±4.9
a. versus b. Po0.05 Po0.05 NS NS Po0.05 NS Po0.05 NS NS NS
b. versus c. Po0.05 NS Po0.05 NS NS NS NS NS NS NS
a. versus c. NS Po0.05 Po0.05 NS Po0.05 NS Po0.05 NS Po0.05 Po0.05
Expression by MSCs
a. Alone 7.4±1.6 7.2±1.3 1.5±0.0 1.5±0.0 1.9±0.7 1.8±0.1 9.7±2.3 9.0±3.8 8.5±2.3 8.3±2.2
b.þhBM-MSCs 4.7±1.1 1.7±0.6 1.4±0.1 7.5±1.2 1.7±0.4 2.0±0.3 5.2±1.4 5.3±1.6 4.3±1.2 3.4±1.0
c.þhBM-MSCs* 3.9±0.8 1.6±0.8 1.3±0.3 2.6±0.4 1.5±0.6 3.0±1.1 5.7±0.4 5.9±1.9 6.1±1.9 4.8±1.3
a. versus b. Po0.05 Po0.01 NS Po0.01 NS NS Po0.05 NS Po0.05 Po0.01
b. versus c. NS NS NS Po0.01 NS NS NS NS NS NS
Abbreviations: CLL, chronic lymphocytic leukemia; DLL, delta-like ligand; MFI, mean ﬂuorescence intensity; NS, not signiﬁcant. Mean values±SD of MFI
(n¼12); DLL. The results are expressed as mean of geometric MFI values of either CD73
þCD45
  hBM-MSC or CD19
þCD5
þCD45
þ CLL cell population
expressing Notch ligands and receptors. ANOVA test: *Po0.05, **Po0.01, ***Po0.001 versus IgG-treated control were considered statistically signiﬁcant.
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higher concentrations of GSI XII promoted speciﬁc apoptosis of
CLL cells in both culture conditions. Thus, the reciprocal
interactions among CLL cells via Notch signaling appear to have
an important role in cell survival.
Notch-1, Notch-2 and Notch-4 are involved in MSC-mediated
survival of CLL cells
A dramatic increase of the apoptotic rate of CLL cells, both in
culture alone and in coculture with either hBM-MSCs or hBM-
MSCs* was achieved by blocking each Notch receptor (Table 2,
Figures 4a and b). Interestingly, hBM-MSCs supported CLL cell
survival as efﬁciently as hBM-MSCs* after 3 days of coculture.
Notch-1, -2 and -4 appeared to be mostly involved in both hBM-
MSCs and hBM-MSCs*-mediated CLL cell survival, as previously
shown,
33,37 whereas Notch-3 had only a low impact in the same
conditions. Blockade of Notch-2 signiﬁcantly increased the
percentage of apoptotic CLL cells in coculture with hBM-MSCs*,
whereas blockade of Notch-4 was more effective on CLL cells in
coculture with hBM-MSCs. In presence of anti-Notch-1 or anti-
Notch-3-blocking antibodies, no signiﬁcant differences in the
decrease of viable CLL cells were observed after 3 days of
coculture with either hBM-MSCs or hBM-MSCs*.
Jagged-1, Jagged-2, DLL-3 and DLL-4 are involved in MSC-
mediated survival enhancement of B-CLL cells
By blocking Jagged-1, -2, DLL-3 or -4 a signiﬁcant reduction of CLL
cell survival was achieved in both culture conditions (Table 2). By
contrast, blockade of DLL-1 had little effect. The combination of
anti-Jagged-1, -2, DLL-3 and -4 was more efﬁcient in promoting
apoptosis of CLL cells cultured in both conditions. The addition of
anti-DLL-1 to the mixture of anti-Jagged-1, -2, DLL-3 and -4 did not
modify CLL cell survival, thus suggesting the major role of the
loop among Notch-1, -2 and -4 and their ligands Jagged-1, -2 and
DLL-3, -4. In addition, these results suggest that Jagged-1, -2, DLL-3
and -4 or Notch-1, -2 and -4 have different downstream targets
involved in the prevention of CLL cell apoptosis. To further
conﬁrm the role of the Notch pathway in CLL cell survival, Notch
receptors were stimulated directly by adding exogenously their
recombinant Notch ligands. We observed that biologically active
Jagged-1, -2 and DLL-3, -4 signiﬁcantly enhanced the survival
of CLL cells when cultured alone, whereas DLL-1 did not
(Supplementary Figure 1). Blockade of Jagged-1, -2, DLL-3 and
-4 or Notch-1, -2 and -4 only on either hBM-MSCs or hBM-MSCs*
signiﬁcantly decreased the survival of CLL cells in coculture
conditions (data not shown). The survival of CLL cells previously
incubated with antibodies against Jagged-1, -2, DLL-3 and -4 or
Notch-1, -2 and -4 also signiﬁcantly decreased in coculture with
either hBM-MSCs or hBM-MSCs* (data not shown). Thus, Jagged-1,
-2, DLL-3 ligands as well as Notch-1, -2 and -4 receptors expressed
by both cell types resulted involved in CLL cell survival.
Molecular pathways involved in Notch-1, Notch-2 and Notch-4-
dependent antiapoptotic effect of MSCs on CLL cells
To identify the downstream targets of Notch signaling pathway
involved in the prevention of CLL cell apoptosis after direct
contact with either hBM-MSCs or hBM-MSCs*, we assessed by ﬂow
cytometry the expression of IL-7R, VEGFR2, active caspase-3, CD23,
Bcl-2, p53 and NF-kB by CLL cells cocultured for 3 days (Figures 5a–g).
We observed that VEGFR2 and active caspase-3 were weakly
expressed by CLL cells at basal conditions, whereas IL-7R, CD23,
Bcl-2, p53 and NF-kB were highly expressed, as previously
shown.
6,38 Active caspase-3 downregulation and IL-7R, CD23,
Bcl-2, p53 and NF-kB overexpression by CLL cells were even more
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Figure 1. The speciﬁc relative cell viability (%) of CLL cells cultured alone with increasing concentrations of chemotherapeutic agents for 1 day.
CLL cells were cultured alone with increasing concentrations of GSI XII (a), Fludarabine (b), Cyclophosphamide (c), Bendamustine (d),
Prednisone (e) and Hydrocortisone (f) for 1 day. Viable CLL cells were quantiﬁed by ﬂow cytometry as percentage of Annexin V
 /7-AAD
 
(lower left quadrant) after electronic gating on CD5
þCD19
þCD45
þ CLL cells. The percentage of speciﬁc viable CLL cells was calculated
according to the following formula: 100-((test (inhibitor-induced apoptosis)–control (spontaneous apoptosis)) 100/(100–control)).
30
Statistical analysis was carried out by using one-way analysis of variance, Holm–Sidak test. *Po0.05 was considered statistically signiﬁcant.
Data were represented as mean±SD of twelve independent experiments.
Notch-mediated stromal support to CLL cells
AHN Kamdje et al
4
Blood Cancer Journal & 2012 Macmillan Publishers Limitedevident following coculture of CLL cells with hBM-MSCs.
Accordingly, active caspase-3 downregulation and IL-7R, CD23,
Bcl-2, NF-kB upregulation were reverted by adding either the
mixture of anti-Notch-1þanti Notch-2þanti-Notch-4 antibodies
or GSI XII, whereas p53 expression remained unchanged, as
previously shown for Notch-1.
39 The addition of blocking anti-
Notch-3 had little effect on the expression of active IL-7R, VEGFR2,
active caspase-3, CD23, Bcl-2 and NF-kB by CLL cells in coculture
(data not shown).
Western blot analysis was performed to verify the targets
inhibited by the Notch pathway. As shown in Figure 5h,
the treatment of CLL cells with either the mixture of anti-
Notch-1þNotch-2þNotch-4 antibodies or GSI XII resulted in
the loss of protein 2 (c-IAP2), Bcl-2, NF-kB and Hes-1 protein
expression followed by a remarkable increase in PARP degrada-
tion. These data conﬁrmed the speciﬁc inhibition of the
Notch pathway in CLL cells following the treatment with
inhibitors. Moreover, the addition of recombinant IL-7 signiﬁcantly
increased the survival of CLL cells cocultured with hBM-MSCs or
hBM-MSCs* (data not shown), whereas IL-6 did not, as previously
reported.
6
Notch-1, Notch-2 and Notch-4 promote the chemo-resistance of
CLL cells in contact with MSCs
CLL cells were cultured with or without hBM-MSCs or hBM-MSCs*,
in absence or presence of drugs, by adding either the mixture of
anti-Notch-1, -2, -4 or GSI XII for 3 days. Drugs promoted apoptosis
of CLL cells when cultured alone, whereas a consistent increase in
the overall number of viable CLL cells was observed in coculture
with MSCs, as previously shown.
3,4,39–43 Interestingly, blockade of
Notch-1, -2 and -4 or all Notch signaling by GSI XII in presence of
Fludarabine, Cyclophosphamide, Bendamustine, Prednisone and
Hydrocortisone dramatically decreased the total number of viable
CLL cells even when cocultured with MSCs (Supplementary
Table 2, Figure 6). To verify whether there was a direct functional
link between Notch pathway and drug-induced apoptosis, we
assessed by ﬂow cytometry the effect of the blockade of Notch-1,
-2 and -4 or whole Notch signaling on the expression of active
caspase-3, Bcl-2, NF-kB, p53 in CLL cells in culture and coculture
conditions in presence of drugs for 3 days. Active caspase-3 was
overexpressed by CLL cells when cultured alone in presence of
drugs, whereas Bcl-2, NF-kB and p53 were only weakly expressed
(Supplementary Figure 2). Active caspase-3 downregulation and
Bcl-2, NF-kB, and p53 overexpression by CLL cells were further
observed following coculture of CLL cells with hBM-MSCs in
presence of drugs. By contrast, active caspase-3 downregulation
and Bcl-2 and NF-kB overexpression were reverted by adding
either the mixture of anti-Notch-1þanti-Notch-2þanti-Notch-4
antibodies or GSI XII in presence of drugs, whereas p53 expression
remained unchanged.
In the same conditions, no proliferation of CLL cells in coculture
with either hBM-MSCs* or hBM-MSCs was observed. In all samples,
following drugs addition, we found a signiﬁcant decrease in the
percentage of CLL cells in S-phase and a signiﬁcant increase of
those in G0G1-phase, with a very low proportion of CLL cells in
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Figure 2. Effects of GSI XII, Fludarabine, Cyclophosphamide, Bendamustine, Prednisone and Hydrocortisone on the active caspase-3
expression by hBM-MSCs. MFI of active caspase-3 expression by CD73þCD45-hBM-MSCs after culture for 3 days with increasing
concentrations of GSI XII (a), Fludarabine (b), Cyclophosphamide (c), Bendamustine (d), Prednisone (e) and Hydrocortisone (f). Statistical
analysis was carried out by using analysis of variance test, Holm–Sidak test. Data were represented as mean±SD of 12 independent
experiments. *Po0.05, **Po0.01, ***Po0.001 versus IgG control were considered statistically signiﬁcant. GSI XII and Fludarabine were
resuspended in dimethyl sulfoxide (DMSO). Cyclophosphamide, Bendamustine, Prednisone and Hydrocortisone were resuspended in NaCl
(0.9%). DMSO and NaCl (0.9%) were used as controls for vehicle effects.
Notch-mediated stromal support to CLL cells
AHN Kamdje et al
5
& 2012 Macmillan Publishers Limited Blood Cancer JournalG2/M phases, with no signiﬁcant differences between hBM-MSCs
and hBM-MSCs* (Supplmentary Table 3).
MSC-mediated survival of CLL cells requires both cell contact and
soluble factors
Coculture of CLL cells with hBM-MSCs in Transwell conditions
resulted in loss of the protective effect of MSCs (data not shown),
according to previous data.
6,8 However, the supernatant obtained
from 1-day culture of hBM-MSCs signiﬁcantly increased the
survival of CLL cells as compared with CLL cells cultured alone
for 5 days (47.1±10.5% (cultureþRPMI) versus 63.7±5.2%
(cultureþsupernatant), Po0.05). Furthermore, similar results
were obtained by coculturing CLL cells with hBM-MSCs* in the
same experimental conditions (data not shown). Blocking
antibodies signiﬁcantly decreased CLL cell survival in Transwell
coculture conditions, even by coculturing CLL cells with hBM-
MSCs* (data not shown). Thus, both soluble factors and adherence
of CLL cells to MSCs are required to obtain protection from
apoptosis, as previously shown.
6,8
Regulatory properties of MSCs from CLL patients
We asked whether hBM-MSCs from CLL patients had the same
immune regulatory properties of hBM-MSCs from normal donors.
T and NK cell proliferation was similarly inhibited by hBM-MSCs*
and hBM-MSCs, and the differences were not statistically
signiﬁcant (data not shown). By contrast, we observed that both
hBM-MSCs* and hBM-MSCs signiﬁcantly increased the number of
surviving unstimulated B cells, as compared with that obtained by
culturing B cells alone (data not shown).
32 The reduction in
apoptosis was not associated with B-cell proliferation, according
to previous data,
44 as the proliferation index at day 3 were 1.01
(coculture with hBM-MSCs*) versus 1.03 (coculture with hBM-
MSCs). When grown on a layer of hBM-MSCs* or hBM-MSCs, the
proportion of B cells in the G0G1-phase increased substantially,
with a concomitant decrease in the proportion of cells in the S and
G2/M phases, as compared with what obtained by culturing B cells
alone (data not shown).
DISCUSSION
It is well known that BM-MSCs promote the growth and
accumulation of normal B cells and CLL cells
7–13 and normally
express molecules of the Notch family that are strictly related to
some of their functions.
33,45,46 However, it is unknown whether
Notch signaling pathway has a role in promoting chemoresistance
upon contact with BM stromal cells during the leukemogenic
process.
In this study, we found that Notch-1, -2 and -4 were involved in
stroma-dependent CLL cell resistance to Fludarabine, Cyclopho-
sphamide, Bendamustine, Prednisone and Hydrocortisone. CLL
cells cultured alone underwent progressive and time-dependent
apoptosis, as previously reported,
9 whereas MSCs dramatically
increased the survival of CLL cells, as previously shown.
8–13
Autologous BM-MSCs obtained from CLL patients supported the
survival of both normal B cells and CLL cells in a similar manner
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Figure 3. Percentage of viable CLL cells and speciﬁc relative
cell viability (%) of CLL cells cultured alone or cocultured with
hBM-MSCs in presence of increasing concentrations of GSI XII.
(a) Percentage of viable CLL cells cultured alone or cocultured with
hBM-MSCs at 10/1 ratio for 3, 7 and 28 days. (b, c) Speciﬁc relative
cell viability (%) of CLL cells was evaluated by culturing alone
or coculturing CLL cells with hBM-MSCs at 10/1 and 1/1 ratios
in presence of increasing concentrations of GSI XII for 3 days.
Statistical analysis was carried out by using one-way analysis
of variance, Holm–Sidak test. *Po0.05 versus control was
considered statistically signiﬁcant. Data were represented as
the mean±SD of 12 independent experiments. GSI XII was
resuspended in dimethyl sulfoxide (DMSO) and DMSO was used
as control for vehicle effects.
Table 2. CLL cell survival following blockade of Notch receptors and
ligands
Treatment þ hBM-MSCs
(% of viable
cells)
þ hBM-MSCs*
(% of viable
cells)
ANOVA test
(a. versus b.)
CLL alone
(% of viable
cells)
No treatment 94.8 (5.3) 89.5 (10.1) NS 62.3 (14.4)
Anti-Notch-1 79.6 (8.5)* 67.0 (6.2)* NS 37.2 (7.9)*
Anti-Notch-2 64.2 (7.9)* 52.6 (6.8)** * 26.6 (8.7)**
Anti-Notch-3 89.3 (7.3) 82.0 (15.1) NS 53.08 (15.6)
Anti-Notch-4 44.4 (11.5)*** 57.1 (7.5)** * 27.2 (8.2)**
Anti-Notch-
1/-2/-4
35.3 (9.6)*** 34.6 (9.3)*** NS 14.6 (7.5)***
Anti-Notch-
1/-2/-3/-4
32.6 (8.2)*** 33.8 (6.7)*** NS 12.8 (2.0)***
Anti-Jagged-1 69.4 (11.4)* 69.4 (8.3)* NS 35.6 (8.8)*
Anti-Jagged-2 67.8 (11.9)* 68.8 (7.5)* NS 35.8 (7.2)*
Anti-DLL-1 87.6 (12.2) 88.8 (10.3) NS 65.5 (16.8)
Anti-DLL-3 72.3 (10.7)* 63.9 (6.2)* NS 35.3 (4.8)*
Anti-DLL-4 70.3 (9.3)* 64.1 (8.5)* NS 33.5 (8.1)*
Anti-Jagged-
1/-2, DLL-3/-4
38.1 (8.5)*** 37.3 (9.3)*** NS 15.7 (3.8)***
Anti-Jagged-
1/-2, DLL-1/-
3/-4
36.8 (9.4)*** 34.3 (8.6)*** NS 13.5 (2.1)***
GSI XII 33.3 (9.2)*** 35.1 (8.3)*** NS 14.4 (3.8)***
DMSO 89.6 (14.6) 85.5 (12.3) NS 63.1 (23.4)
Abbreviations: ANOVA, analysis of variance; Anti-, blocking antibody;
CLL, chronic lymphocytic leukemia; DLL, delta-like ligand; NS, not
signiﬁcant; DMSO, dimethyl sulfoxide. Values are percentages of overall
viable human CLL cells (mean±SD of 12 independent experiments);
DMSO is the vehicle control for GSI XII, 7.5mM. Data were represented as
mean±SD of 12 independent experiments. Statistical analysis was done
using ANOVA test. *Po0.05, **Po0.01, ***Po0.001 versus IgG-treated
control was considered statistically signiﬁcant.
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reverted by inhibiting the entire Notch signaling pathway with GSI
XII, thus suggesting that some molecules of the Notch pathway
were involved in the phenomenon. This evidence supports
the concept that Notch signaling has a direct role in CLL cell
survival via the reciprocal interactions among leukemia cells,
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antibodies anti-Notch receptors or GSI XII. B-CLL cells were cultured alone or cocultured with either hBM-MSCs (a) or hBM-MSCs* (b) (10/1
ratio), in absence or presence of anti-Notch-1, -2, -3, -4 antibodies, or GSI XII for 3 days. Percentage of viable CLL cells (Annexin V
 /7-AAD
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lower left quadrant) was measured by ﬂow cytometry after electronic gating on CD5
þCD19
þCD45
þ CLL cells. Statistical analysis was carried
out by using one-way analysis of variance, Holm–Sidak test. *Po0.05, **Po0.01, ***Po0.001 versus IgG-treated control were considered
statistically signiﬁcant. GSI XII was resuspended in dimethyl sulfoxide (DMSO) and DMSO was used as control for vehicle effects.
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Figure 5. Expression of IL-7R, VEGFR2, active caspase-3, Bcl-2, CD23, c-IAP protein, NF-kB and Hes-1 in CLL cells cocultured with hBM-MSCs.
The expression of IL-7R (a), VEGFR2 (b), active caspase-3 (c), CD23 (d), Bcl-2 (e), p53 (f) and NF-kB( g) by CD5
þCD19
þCD45
þ CLL cells was
analyzed by ﬂow cytometry following coculture with hBM-MSCs (10/1 ratio), in absence or presence of anti-Notch-1,-2 or -4 antibodies or GSI
XII for 3 days. Western blot analysis was performed to assess the expression of c-IAP2, Hes-1, PARP, NF-kB and Bcl-2 by CLL cells cocultured
with hBM-MSCs in the same conditions (h). Hes-1 expression was used as functional read-out for Notch activation. NF-kB and Bcl-2 expression
was evaluated to conﬁrm CLL cell activation following coculture with hBM-MSCs in the same conditions. b-actin was included as loading
control. Statistical analysis was carried out by using one-way analysis of variance, Holm–Sidak test. *Po0.05, **Po0.01, ***Po0.001 versus IgG-
treated control were considered statistically signiﬁcant. GSI XII was resuspended in dimethyl sulfoxide (DMSO) and DMSO was used as control
for vehicle effects.
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the presence of stromal cells signiﬁcantly enhanced this
phenomenon. In fact, CLL cells and MSC coculture led to the
signiﬁcant overexpression of DLL-3, Notch-1 and -4 by CLL cells, as
well as of Notch-4 only by hBM-BMSCs, but not hBM-MSCs*.
Blocking and stimulating experiments demonstrated that Jagged-
1/-2 and DLL-3/-4 ligands synergistically interact with Notch-1,
-2 and -4 and are important components of the stromal cell-
mediated antiapoptotic effect observed in cocultured CLL cells.
Blocking antibodies against all Notch receptors and ligands but
Notch-3 or DLL-1 decreased the survival of CLL cells even when
cultured alone. Thus, the reciprocal interactions among CLL cells
via Notch signaling also have an important role in cell survival.
Coculture experiments of CLL cells with hBM-MSCs in Transwell
conditions showed that the enhancement of CLL cell survival is
not only due to the direct contact of CLL cells with MSCs, but also
to soluble factors released by MSCs, such as IL-7 and VEGF, as
previously shown.
6–8 Furthermore, Notch-1, -2 and -4-dependent
pro-survival effect by hBM-MSCs was associated to the
maintenance of IL-7R, CD23, Bcl-2, NF-kB, protein 2 (c-IAP2) and
Hes-1 expression by CLL cells, together with the downregulation
of active caspase-3, without affecting p53 expression. These
ﬁndings are in agreement with previous data describing the role
of Bcl-2 and NF-kB signaling in the persistence of CLL residual
clones following chemotherapy
47–48 and demonstrating that BM-
MSCs may protect CLL cells from drug-induced apoptosis.
1,4,49
In addition, our data suggest that Notch-1, -2 and -4 are involved
in the chemo-resistance of CLL cells in direct contact with hBM-
MSC following drugs exposure. We found that Notch-1, -2 and -4
signaling upregulates Bcl-2 and NF-kB and downregulates active
caspase-3 expression by CLL cells cocultured with hBM-MSCs or
hBM-MSCs*, in absence or presence of drugs. Previous studies
have shown that VLA-4 engagement by ﬁbronectin induces
in vitro resistance of CLL cells to Fludarabine.
50 Therefore, the
ability of Notch-1, Notch-2, Notch-4 signaling to confer resistance
towards drugs to CLL cells in direct contact with MSCs, by
modulating Bcl-2, NF-kB and p53 expression,
51–53 supports the
concept that this effect may occur at least in part through Bcl-2-,
NF-kB- and p53-dependent mechanisms. In addition, the
involvement of p53 in VLA-4 pathway has been reported to
mediate resistance of CLL cells to drugs.
43,49
Overall, our data show that Notch pathway normally has an
important role in MSC-dependent promotion of the survival and
resistance of CLL cells to drugs. Therefore, the onset of
dysregulated Notch pathway, that is, as a consequence of
mutations occurring in the Notch1 gene, could even enhance
the prosurvival signals that the normal pathway already confers to
CLL cells interacting reciprocally or with BM stromal cells. Thus,
Notch inactivation by speciﬁc inhibitors, as suggested for acute
lymphoblastic leukemia,
3,32 could represent an additional tool to
overcome drug resistance and ameliorate the therapeutic strate-
gies for CLL in both aggressive and indolent phases of the disease.
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